OCUL Ocular Therapeutix, Inc.
Price Chart
Executive Summary
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple data updates on AXPAXLI (OTX-TKI) including results from the SOL-1 Phase 3 superiority trial in wet AMD and a HELIOS program update in NPDR. The conference presentations are scheduled for June 12-13, 2026, in Las Vegas, with a CEO fireside chat and several clinical sessions.
Actionable Insight
The SOL-1 Phase 3 superiority data is the key catalyst to watch at CTS 2026 (June 12-13). Positive efficacy or safety differentiation could drive upside given the 94% bullish analyst consensus and the early-stage biotech stage of Ocular. The HELIOS program update in NPDR may expand the addressable market thesis. Expect high volatility around the conference dates; traders should position ahead of the presentation if prior trial signals were favorable, but note the historical T+20 win rate on OCUL reports is only 30% with negative average alpha.
Key Facts
- SOL-1 Phase 3 superiority trial efficacy outcomes with OTX-TKI in neovascular AMD to be presented at CTS 2026 on June 13
- HELIOS program update on OTX-TKI in nonproliferative diabetic retinopathy (NPDR) also scheduled for June 13
- Safety and tolerability profile of OTX-TKI in neovascular AMD presented separately on the same day
- Pravin U. Dugel, MD (CEO) participating in fireside chat 'From Global KOL to CEO' and panel 'From Innovation to Approval'
- AXPAXLI (OTX-TKI) is an axitinib intravitreal hydrogel based on ELUTYX bioresorbable hydrogel technology, currently in Phase 3 for wet AMD and diabetic retinal disease
Financial Impact
No financial data disclosed; presentations focus on clinical trial results for AXPAXLI. Positive SOL-1 data could support regulatory filings and enhance pipeline value for a $1.8B market cap biotech.
Risk Factors
- SOL-1 Phase 3 data may fail to show superiority vs. existing anti-VEGF standard of care
- Competitive pressure from faricimab and other long-acting agents in wet AMD
- History of substantial negative alpha at T+20 (avg -8.41%) on Ocular reports despite positive near-term moves
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306630 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
Press Release
| $8.80 $8.25 | ▼ −6.25% | ▼ −3.68% | $8.25 (−6.25%) |
|
May 28, 2026
8d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 5, 2026
4w ago
|
8-K
| $9.71 $9.71 | · 0.00% | ▼ −1.38% | $8.25 (−15.04%) |
|
May 5, 2026
4w ago
|
Press Release
| $9.71 $9.71 | · 0.00% | ▼ −1.38% | $8.25 (−15.04%) |
|
Apr 30, 2026
5w ago
|
DEFA14A
| — | awaiting T+1 | — | — |
|
Apr 13, 2026
7w ago
|
Press Release
| $8.86 $8.76 | ▼ −1.13% | ▼ −2.34% | $8.25 (−6.88%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $8.33 $8.49 | ▲ +1.92% | ▲ +1.84% | $8.25 (−0.96%) |
|
Feb 20, 2026
15w ago
|
Insider Cluster
| $7.78 $8.41 | ▲ +8.10% | ▲ +9.11% | $8.25 (+6.04%) |
|
Feb 20, 2026
15w ago
|
Insider Cluster
| $7.78 $8.41 | ▲ +8.10% | ▲ +9.11% | $8.25 (+6.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access